Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9855318 Fusion proteins

Patent 9855318 was granted and assigned to Eli Lilly and Company on January, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Eli Lilly
Eli Lilly
0
Date Filed
April 28, 2016
0
Date of Patent
January 2, 2018
0
Patent Applicant
Eli Lilly
Eli Lilly
0
Patent Application Number
15140519
0
Patent Citations Received
‌
US Patent 11919935 Ultra-long acting insulin-Fc fusion proteins and methods of use
0
‌
US Patent 11667689 Insulin-Fc fusion proteins and methods of use to treat cancer
0
‌
US Patent 11673934 Ultra-long acting insulin-Fc fusion proteins and methods of use
0
‌
US Patent 11707517 Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
0
‌
US Patent 11773151 Ultra-long acting insulin-Fc fusion proteins and methods of use
Patent Inventor Names
Jonathan Wesley Day
0
Andrew Ihor Korytko
0
Craig Duane Dickinson
0
David Bruce Baldwin
0
Gregory Alan Lazar
0
John Michael Beals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
9855318
0
Patent Primary Examiner
‌
Cherie M Stanfield
0

Find more entities like US Patent 9855318 Fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo